Hillevax Inc

NASDAQ HLVX

Data sourced from

and

Download Data

Hillevax Inc Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024: USD -125.57 M

Hillevax Inc Free Cash Flow is USD -125.57 M for the Trailing 12 Months (TTM) ending March 31, 2024, a -69.17% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.

Hillevax Inc Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -74.23 M, a -224.21% change year over year.
Hillevax Inc Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -22.89 M, a -5,390.41% change year over year.
Hillevax Inc Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -417.00 K.

NASDAQ: HLVX

Hillevax Inc

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street, Boston, MA, United States, 02109
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Key trends